Health care company focused on renal and other chronic conditions
Issues related to End Stage Renal Disease (ESRD) and Chronic Kidney Disease; Medicare Secondary Payer; Forecast error adjustment to address workforce crisis; Adjustment of the Prospective Payment System (PPS) payment rate after the Transitional Drug Add-on Payment Adjustment (TDAPA) period ends for new drugs and biological products CMS determines are within an existing ESRD functional category; Creation of incentives to adopt innovation for patients enrolled in Medicare Advantage plans Delay implementation of the ESRD-related drug policy to bring oral phosphate lowering drugs under the Medicare ESRD PPS until the earlier of January 1, 2033 or such time as intravenous options are approved
MMM - Medicare/Medicaid
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
AVENUE SOLUTIONS
401 9th St. NW, Suite 720, Washington, DC, 20004, US
ELIZABETH MACDONALD BARNETT